摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(4-chlorophenyl)amino-5,6-tetramethylenothieno<2,3-d>pyrimidine | 81136-45-0

中文名称
——
中文别名
——
英文名称
4-(4-chlorophenyl)amino-5,6-tetramethylenothieno<2,3-d>pyrimidine
英文别名
N-(4-chlorophenyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine;(4-chloro-phenyl)-(5,6,7,8-tetrahydro-benzo[4,5]thieno[2,3-d]pyrimidin-4-yl)-amine;(4-chlorophenyl)-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)amine;4-(4-chlorophenyl)amino-5,6-tetramethylenothieno[2,3-d]pyrimidine;N-(4-chlorophenyl)-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-amine
4-(4-chlorophenyl)amino-5,6-tetramethylenothieno<2,3-d>pyrimidine化学式
CAS
81136-45-0
化学式
C16H14ClN3S
mdl
MFCD00419586
分子量
315.826
InChiKey
XODTUAAXWAKVRI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    136-138 °C
  • 沸点:
    516.1±50.0 °C(Predicted)
  • 密度:
    1.408±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.3
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    66
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE
    申请人:Bánhegyi Pèter
    公开号:US20110015214A1
    公开(公告)日:2011-01-20
    The invention relates to novel tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, as well as their pharmaceutically acceptable salts. The subject of the invention too the process for producing the compounds and their use as a pharmaceutically active agent and as pharmaceutical compositions for prophylaxis and/or treatment of proliferative diseases such as cancer.
    该发明涉及新颖的三环苯并[4,5]噻吩-[2,3-d]嘧啶-4-基-基衍生物,以及它们的药学上可接受的盐。该发明还涉及制备这些化合物的方法,以及它们作为药用活性剂和用于预防和/或治疗增殖性疾病如癌症的药物组合物。
  • [EN] TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE<br/>[FR] DÉRIVÉS TRICYCLIQUES DE BENZO[4,5]THIÉNO-[2,3-D]PYRIMIDIN-4-YLAMINE, LEURS SELS, PROCÉDÉ DE FABRICATION DES COMPOSÉS ET LEUR UTILISATION PHARMACEUTIQUE
    申请人:VICHEM CHEMIE KUTATO KFT
    公开号:WO2009104026A1
    公开(公告)日:2009-08-27
    The invention relates to novel tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, as well as their pharmaceutically acceptable salts. The subject of the invention too the process for producing the compounds and their use as a pharmaceutically active agent and as pharmaceutical compositions for prophylaxis and/or treatment of proliferative diseases such as cancer.
    本发明涉及新型三环苯并[4,5]噻吩-[2,3-d]嘧啶-4-基基衍生物,以及其药学上可接受的盐。本发明还涉及生产该化合物的方法,以及将其用作药学活性剂和制备用于预防和/或治疗增殖性疾病如癌症的药物组合物。
  • Green catalyst access to thieno [2, 3‐b] pyridines derivatives
    作者:Nawel Mehaoui、Souheyla Boudjema、Zahira Kibou、Noureddine Choukchou‐Braham、Abderrahim Choukchou‐Braham
    DOI:10.1002/jhet.4635
    日期:——
    benefits including a quicker reaction time, an easy set-up, and high yields. Spectroscopic data (IR, +H and 13C NMR spectra) have revealed the structural details of all target compounds. The catalyst was characterized by X-ray diffraction, BET and Fourier-transformed infrared spectroscopy. X-ray diffraction showed that PVW was correctly incorporated on an acid activated clays support. In comparison
    目前的研究重点是使用具有 Keggin 结构并负载在酸活化 (PVW/AAM) 上的磷酸杂多酸 H 4 PW 11 VO 40 ·8 H 2 O (PVW) 合成新取代的 Thieno [2, 3- b] 吡啶衍生物。建议的协议是一种简单、环保的方法,用于在无溶剂反应条件下合成从 3-cyano-2-aminothiopene 获得的 thieno [2,3-b] 嘧啶生物作为构建块。使用合成的 PVW/AAM 催化剂实现了取代的 Thieno [2, 3-b] 吡啶衍生物的优异产率 (60%–97%)。目前的工艺提供的好处包括更快的反应时间、简单的设置和高产率。光谱数据(IR,+ H 和13 C NMR 光谱)揭示了所有目标化合物的结构细节。通过X射线衍射、BET和傅里叶变换红外光谱对催化剂进行了表征。X 射线衍射表明 PVW 正确地结合在酸活化粘土载体上。与母体磷酸相比,PVW
  • Ram; Pandey; Vlietinck, Journal of Heterocyclic Chemistry, 1981, vol. 18, # 7, p. 1277 - 1280
    作者:Ram、Pandey、Vlietinck
    DOI:——
    日期:——
  • Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma
    作者:Min Zhang、Li Jiang、Jia Tao、Zhaoping Pan、Mingyao He、Dongyuan Su、Gu He、Qinglin Jiang
    DOI:10.1016/j.bmc.2019.04.022
    日期:2019.6
    MAP Kinase Interacting Serine/Threonine Kinase 1 (MNK1) play important roles in the signaling transduction of MAPK pathways. It is significantly overexpressed in renal clear cell carcinoma and head-neck squamous cell carcinoma tissues in both mRNA and protein levels. Based on the crystallographic structure of MNK1 protein and binding modes analysis of known MNK inhibitors, we have designed and synthesized a series of 4-aniline-thieno [2,3-d] pyrimidine derivatives as potential MNK1 inhibitors. These synthetic compounds are tested in biochemical and cell proliferation assays, and six of them display potent inhibitory capacity against MNK1 kinase and cancer cell lines. Compound 12dj with strongest inhibitory capacity is transferred to molecular mechanism studies, and the results indicated that 12dj remarkably suppresses the phosphorylation of EIF4E, a substrate of MNK1. And the expression levels of MNK1, ERK1/2 and pERK1/2 are not affected by compound 12dj incubation in SUNE-1 and 786-O cells. In summary, our works suggested that these novel 4-aniline-thieno[2,3-d]pyrimidine based MNK1 inhibitors might be attractive lead compounds for targeted therapy of renal cell carcinoma and nasopharyngeal carcinoma.
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-腈 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2-乙酸,1,4-二氢-4-羰基-5-苯基-,甲基酯 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(4-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙酸,[[5-(4,5-二甲基-2-苯基噻吩并[2,3-d]嘧啶-6-基)-1,3,4-噁二唑-2-基]硫代]-,乙基酯 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇